Elucidation and overcoming of drug resistance mechanism mediated by semaphorin 3A signal in multiple myeloma

Research Project

Project/Area Number	18K08373
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 54010:Hematology and medical oncology-related
Research Institution	Tokai University
Principal Investigator	SUZUKI Rikio 東海大学, 医学部, 講師 (70514371)
Project Period (FY)	2018-04-01 – 2022-03-31
Project Status	Completed (Fiscal Year 2021)
Budget Amount *help	¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000) Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords	多発性骨髄腫 / セマフォリン3A / 薬剤耐性機序 / 骨髄間質細胞 / 骨芽細胞 / 骨髄微小環境 / 骨細胞 / PI3K-AKT / 転換 / furin / CDK5 / ボルテゾミブ耐性 / ニューロピリン1 / FPPC
Outline of Final Research Achievements	In this study, we aimed to clarify the significance of the interaction between semaphorin 3A (SEMA3A) and neuropilin 1 (NRP1) in adhesion-mediated drug resistance between multiple myeloma (MM) cells and bone marrow stromal cells (BMSCs). We found that SEMA3A is secreted from bone marrow stromal cells, and synergistically cooperates with cytokines such as IGF-1 to promote proliferation of BMSCs at least partly via the SEMA3A-NRP1 pathway in the bone marrow microenvironment. We also found that SEMA3A can overcome the drug resistance mechanism induced by adhesion between MM cells and BMSCs by inducing and promoting the differentiation of bone marrow stromal cells into osteoblasts partly via the AKT pathway.
Academic Significance and Societal Importance of the Research Achievements	MM細胞により誘導する多彩な薬剤耐性メカニズムにより本疾患は不治の病のままであり、その克服が急務である。SEMA3Aは骨髄間質細胞を骨芽細胞方向へ形質を変化させることで細胞間接着を介した薬剤耐性を解除し、その結果薬剤感受性を回復させると考えられる。更には、代表的なMM治療薬との併用により、その作用が更に増強されることから、今後のMM治療においてSEMA3Aは有望な治療オプションの一つとして、世界的にもMM患者の予後改善に大きく貢献する可能性がある。